Andere talen Biofrontera AG

Aandelen

Vertraagde tijd Xetra Andere beurzen 17:36:21 24-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,334 ^EUR	-3,47%		-4,57%	-16,71%

11/03	Biofrontera dient een prospectus in voor potentiële secundaire aandelenaanbiedingen	MT
2023	Biofrontera AG rapporteert resultaten voor het derde kwartaal en de negen maanden eindigend op 30 september 2023	CI

Biofrontera : Abstimmungsergebnisse	04/04
Biofrontera Files Prospectus for Potential Secondary Stock Offerings	11/03
Medicus Pharma Names COO	05/03
BIOFRONTERA AG ANNOUNCES REVISED STRATEGY	21/02
BIOFRONTERA AG, BIOFRONTERA TRANSFERS CLINICAL RESEARCH TO THE U.S.	21/02
MORNING BRIEFING - Deutschland/Europa -2-	16/02
Biofrontera AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	28/11
Earnings Flash (BFRI) BIOFRONTERA Reports Q3 Revenue $8.9M, vs. Street Est of $8.4M	09/11
Biofrontera Licensor Gets FDA Approval for New Formulation of Ameluz to Treat Actinic Keratosis	10-10-23
Biofrontera Says Sun Pharmaceutical Alleging Breach of Contract In Lawsuit	03-10-23
Biofrontera AG Reports Earnings Results for the Half Year Ended June 30, 2023	31-08-23
Biofrontera Says Skin Disease Therapy Was Well-Tolerated in Phase 1 Safety Trial	28-08-23
Earnings Flash (BFRI) BIOFRONTERA Reports Q2 Revenue $5.8M	11-08-23
Biofrontera Completes Patient Enrollment in Skin Cancer Treatment Study	10-08-23
Top Premarket Decliners	21-07-23
Biofrontera Launches Novel Belixos Active Care	05-07-23
Biofrontera to Effect 1-for-20 Reverse Stock Split	03-07-23
Wall Street Set to Open Lower; Housing Starts Rise More Than Expected	20-06-23
Biofrontera AG Reports Earnings Results for the First Quarter Ended March 31, 2023	31-05-23
Biofrontera AG Completes Patient Recruitment of Ameluz Phase I Trial	17-05-23

Geen resultaten voor deze zoekopdracht